Development of BIO 300 as a regenerative therapy for triple negative breast cancer

Grant Project Details:

Artur Serebrenik, PhD
Humanetics Corporation | ,
In Process
View all grants awarded

Grant timeline: proposal, updates, reports

Grant Location

Humanetics Corporation

Grant Description

The primary goal of the proposed work is to produce preclinical data to support the use of BIO 300 in patients with triple negative breast cancer receiving radiotherapy to improve patient survival by preventing metastasis to the lungs. The secondary goal is to further characterize the mechanism by which BIO 300 is able to protect normal tissues from the harmful side effects of radiotherapy. Ultimately, since BIO 300 is already being used clinically for other indications, our overarching goal is to generate a body of data that will support the initiation of a clinical study in patients with triple negative breast cancer.

Grant Awardee Biography

Artur Serebrenik, PhD